Curcumin Harmine Isovanillin Formulation for SARS-CoV-2 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for COVID-19, including vaccines and medications, are inadequate in inhibiting the replication of the SARS-CoV-2 virus and reducing transmission, especially with the emergence of variants like Delta and Omicron that evade current protocols, leading to ongoing high transmission and severe symptoms.
Innovation Solution
A multiple-component antiviral formulation comprising curcumin, harmine, and isovanillin, which are synergistically combined to inhibit SARS-CoV-2 virus replication, administered prophylactically or therapeutically to prevent or ameliorate COVID-19 symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments and vaccines are used, then some level of protection is provided, but they are inadequate in inhibiting SARS-CoV-2 replication and reducing transmission, especially with variants
Solution Approach 1:
The patent applies the composite materials principle by combining three distinct active ingredients (curcumin, harmine, and isovanillin) into a single formulation. Each component contributes different mechanisms of antiviral action, creating a composite therapeutic agent that addresses multiple aspects of viral replication and transmission, thereby improving both reliability and adaptability against variants.
Solution Approach 2:
The formulation segments the antiviral action into three distinct components, each targeting different stages or mechanisms of viral replication. This segmentation allows the treatment to maintain effectiveness even when viral variants evade one particular mechanism, as the other components continue to provide protective action.
2Reliability
If multiple-component formulations are used, then antiviral effectiveness is improved, but formulation complexity increases
Solution Approach 1:
The patent merges three separate active ingredients into a single integrated formulation that can be administered together. This combining approach delivers multiple antiviral mechanisms simultaneously, improving effectiveness while maintaining a practical, unified dosage form that does not require separate administration of multiple drugs.
3Productivity
If new treatments are developed to inhibit viral replication, then transmission reduction is achieved, but the virus mutates into variants that evade current protocols
Solution Approach 1:
By using a composite formulation with three different active ingredients that target various aspects of viral replication, the treatment creates multiple barriers to viral reproduction. This multi-target approach reduces the likelihood that viral mutations will successfully evade all mechanisms simultaneously, thereby maintaining protocol effectiveness against emerging variants.
Data Source
AI summary
Formulations for treatment of human subjects exposed to, or potentially exposed to SARS-CoV-2 virus, or suffering from COVID-19, comprising a multiple-component antiviral formulation comprising a curcumin component, harmine component, and isovanillin component, and/or variants thereof. The formulation may also be used to inhibit SARS-CoV-2 virus in cell-based assays or in the manufacture of antiviral medicaments.